Get started
PfizerPfizerPfizer

Pfizer

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options Bonds

PFE trade ideas

Tensions in the Pharma Sector and Signs of U.S. StagflationBy Ion Jauregui – Analyst at ActivTrades The U.S. biopharmaceutical industry may soon face significant regulatory changes. According to sector sources, the Trump administration is evaluating a proposal to tie U.S. drug prices to the lowest prices available in other developed countries. This initiative, viewed by companies such as Pfizer Inc. (NYSE: PFE) and Merck & Co. Inc. (NYSE: MRK) as a direct threat to innovation, could redefine the global balance of the pharmaceutical sector. Macroeconomic Outlook: Stagflation Warning On the macroeconomic front, Citigroup Inc. (NYSE: C) has warned that despite current signs of consumer activity, the negative effects on growth are expected to intensify in the second half of the year. Nathan Sheets, the bank’s Chief Economist, points to rising risks of stagflation, in a context marked by declining confidence and renewed criticism from Donald Trump towards Federal Reserve Chair Jerome Powell. Defense Sector: Tariff Impact Raytheon Technologies (NYSE: RTX) has stated that new tariffs proposed by the Trump administration could have a negative impact of up to $850 million on its 2025 earnings. Nevertheless, the company exceeded market expectations in its latest quarterly results and reaffirmed its annual guidance. Shareholder Reshuffle at BP Activist fund Elliott has acquired a 5.006% stake in BP plc (LON: BP), surpassing the regulatory threshold in the United Kingdom and becoming the company’s second-largest shareholder—behind BlackRock (9.2%) and ahead of Vanguard (4.95%). This strategic move reflects the increasing shareholder pressure on major oil companies. Key Events of the Day Notable economic indicators and corporate earnings scheduled for today include: • S&P Global Manufacturing PMI • S&P Global Services PMI • Earnings reports from: Philip Morris (PM), IBM (IBM), AT&T (T), Thermo Fisher Scientific (TMO), ServiceNow Inc. (NOW), Boston Scientific (BSX), Texas Instruments (TXN), Boeing (BA), O’Reilly Automotive (ORLY), Chipotle Mexican Grill (CMG) These releases are expected to have a significant impact on markets, particularly across the consumer, technology, and defense sectors. ******************************************************************************************* The information provided does not constitute investment research. The material has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and such should be considered a marketing communication. All information has been prepared by ActivTrades ("AT"). The information does not contain a record of AT's prices, or an offer of or solicitation for a transaction in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. Any material provided does not have regard to the specific investment objective and financial situation of any person who may receive it. Past performance is not reliable indicator of future performance. AT provides an execution-only service. Consequently, any person acting on the information provided does so at their own risk.
NYSE:PFEShort
by ActivTrades
PFEAt the current price, I'm looking for a retest toward the daily target zone located on the chart. On 3/21 PFE announced news about dropping the decision to move forward with the weight loss drug. Since then, price dropped down in spike like fashion. After the big volume spike, on that date, volume cam down and slowly started to build up again for the bears but there may be some weakness here. I wonder if this is a good price range where short sellers are starting to get concerned? I don't care for news and and am mainly a volume trader. So this trade will be interesting and maybe we get some attention at some point. If price goes lower, we will revisit if another opportunity presents itself.
NYSE:PFELong
by Redimere_91
The Collaborative Edge: Pfizer's Innovation Secret? Pfizer's success in the biopharmaceutical industry hinges on its internal capabilities and a strategic embrace of external collaboration. This proactive approach, spanning diverse technological frontiers, fuels innovation across its operations. From partnering with QuantumBasel and D-Wave to optimize production planning using quantum annealing, to collaborating with XtalPi to revolutionize drug discovery through AI-powered crystal structure prediction, Pfizer demonstrates the tangible benefits of cross-industry partnerships. These initiatives showcase a commitment to exploring cutting-edge technologies to enhance efficiency and accelerate the identification of promising drug candidates, ultimately improving patient outcomes and strengthening Pfizer's competitive position. The article highlights specific examples of Pfizer's collaborative endeavors. The Pfizer Healthcare Hub in Freiburg acts as a catalyst, connecting internal needs with external innovation. The successful proof of technology in production planning using quantum annealing resulted in significant time and resource savings. Furthermore, the partnership with XtalPi has dramatically reduced the timeframe for determining the 3-D structure of potential drug molecules, enabling faster and more efficient drug screening. These collaborations exemplify Pfizer's strategic focus on leveraging specialized expertise and advanced technologies from external partners to overcome complex challenges in the pharmaceutical value chain. Beyond these specific projects, Pfizer actively engages with the broader quantum computing landscape, recognizing its transformative potential for drug design, clinical studies, and personalized medicine. Collaborations with technology giants like IBM and fellow pharmaceutical companies underscore the industry-wide interest in harnessing the power of quantum computing. While the technology is still in its early stages, Pfizer's proactive participation in this collaborative ecosystem positions it at the forefront of future healthcare breakthroughs. This commitment to synergy, from basic research to market research, underscores a fundamental belief in the power of working together to drive meaningful advancements in the pharmaceutical industry.
NYSE:PFELong
by UDIS_View
12/23/24 - PFE: new BUY mechanical signal.12/23/24 - PFE: new BUY signal chosen by a rules based, mechanical trading system. PFE - BUY Stop Loss @ 24.80 Entry BUY @ 26.71 Target Profit @ 29.54 Analysis: 1. On the Higher timeframe - Prices have stayed above the lower channel line of the ATR (Average True Range) Channel 2. Higher timeframe - Trader Vic's (Victor Sperandeos) 1-2-3/2B Buy pattern...where the lowest current bottom breakout price is greater than the preceding bottom price
NYSE:PFE
by martinmlm
Pfizer Wave Analysis – 27 March 2025 - Pfizer broke support level 25.20 - Likely to fall to support level 24.70 Pfizer recently broke the pivotal support level 25.20 (lower border of the sideways price range inside which the price has been moving from November). The breakout of the support level 25.20 accelerated the active impulse wave c of the higher impulse wave B from Janaury. Given the clear daily downtrend, Pfizer can be expected to fall to the next support level 24.70 (former strong support from November and the target for the completion of the active wave B).
NYSE:PFEShort
by FxProGlobal
Pfizer: Oh Buyer Where Art Thou?Pfizer has struggled for years, and some traders may see risk of further downside. The first pattern on today’s chart is the slide to a new 12-year low in October and November. The drugmaker barely retraced half that move at subsequent highs. It also remained mostly below its October low of $26.87. That may suggest old support has become new resistance. Second is PFE’s price action at its 100-day simple moving average (SMA). It fell sharply after breaking that SMA in October and now seems to be stalling at the same line. (See white arrows.) That may reflect a longer-term downtrend. Third, $25.53 was the weekly close in mid-February. It provided support earlier this month, but yesterday the stock returned to the same level. Could that trigger a breakdown? Next, the 50-day SMA had a “death cross” under the 200-day SMA in late November. The 100-day SMA followed in December. The resulting alignment, with faster SMAs under slower ones, is potentially consistent with a downtrend. Finally, PFE is an active underlier in the options market. (TradeStation data shows it ranking 13th in the S&P 500 in the last month, averaging about 110,000 contacts per day.) That could make it easier to position for moves with calls and puts. TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. If you're born to trade, we could be for you. See our Overview for more. Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options or futures); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors. Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission and a futures commission merchant licensed with the Commodity Futures Trading Commission). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association, and a number of exchanges. Options trading is not suitable for all investors. Your TradeStation Securities’ account application to trade options will be considered and approved or disapproved based on all relevant factors, including your trading experience. See www.TradeStation.com . Visit www.TradeStation.com for full details on the costs and fees associated with options. Margin trading involves risks, and it is important that you fully understand those risks before trading on margin. The Margin Disclosure Statement outlines many of those risks, including that you can lose more funds than you deposit in your margin account; your brokerage firm can force the sale of securities in your account; your brokerage firm can sell your securities without contacting you; and you are not entitled to an extension of time on a margin call. Review the Margin Disclosure Statement at www.TradeStation.com . TradeStation Securities, Inc. and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., both operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.
NYSE:PFE
by TradeStation
FEAR PRESENTS A BUYING OPPORTUNITYThe deteriorating sentiment over the last 3 years has created a substantial buying opportunity. The negative sentiment can be attributed to 4 main things- decreased EPS/ Net Income since 2022/2023 (end of COVID $$), increased debt levels post-Seagen acquisition and revenue challenges due to upcoming patent expirations. While these concerns are not unwarranted, it is important to note that Pfizer has been through several patent cliffs before while simultaneously growing dividends . The notable upcoming expirations include the pneumonia shot Prevnar in 2026 and the cancer drugs Ibrance and Xtandi, both in 2027. Pfizer has an exceptional history of capital preservation and therefore will continue to take action to address any potential revenue shortfalls including aggressive cost-cutting measures already in progress. From a valuation perspective, PFE's shiller PE is currently 9.51 or 94% as low as it has been in the last 10 years and also 89% better than 462 companies in the drug manufacturing industry. Seeking Alpha gives PFE a grade of F on Growth, but when looking at the individual characteristics not 1 is below a D and only two are D's, and in aggregate looks much better than SA is portraying with a grade of F. Pfizer should not usually be expected to be a grower as it is a mature company. From a technical standpoint it looks like a double bottom is forming at the bottom of a 12 year trend line. The Price/ FCF and EV/EBITDA ratios have decreased back to 2023 and prior levels indicating it is no longer overvalued as it was in 2024. Reverse DCF based on EPS w/out NRI and an 11% discount rate show thaf Pfizer's fair value is $35.89, indicating a 27% margin of safety. The recent volume shows large-scale buying, probably by institutions. Overall I believe the negative sentiment mostly due to the upcoming patent expiration and the realization of loss of revenue from COVID era $ is currently baked into the price and presents a decent buying opportunity.
NYSE:PFELong
by Jrussell86
PFE Operation PlanFor this trade on Pfizer (PFE), we will implement a staggered entry strategy with three designated entry points at $26, $25, and $24.5. This approach allows for a cost-averaging method and improved risk management as the market fluctuates. Our profit targets are set at $28, $30.5, and $31, ensuring we capture gains incrementally as the price moves upward. These targets are based on our technical analysis and current market dynamics. Additionally, strict stop-loss protocols will be in place to mitigate downside risks. Disclaimer: This information is provided for educational and informational purposes only and should not be considered financial advice. Trading involves substantial risk, and past performance is not indicative of future results. Always conduct your own research or consult a professional financial advisor before making any investment decisions.
NYSE:PFELong
by Robert_V12
Pfizer ($PFE): Undervalued Pharma Giant with Growth Potential?(1/9) Good afternoon, everyone! 😊 Pfizer ( NYSE:PFE ): Undervalued Pharma Giant with Growth Potential? With PFE at $25.90, is this the time to buy into this pharmaceutical powerhouse? Let’s dive in! 😎 (2/9) – PRICE PERFORMANCE • Current Price: $25.90 as of March 12, 2025 😏 • Recent Moves: Trading within a range of $24 to $28, currently near the middle 😬 • Sector Vibe: Pharma sector remains stable, with new drug approvals driving growth 📈 Short commentary: The stock seems to be consolidating. Is this a good entry point? 🤔 (3/9) – MARKET POSITION • Market Cap: Approximately $147.2 billion (assuming 5.67 billion shares outstanding) 💰 • Operations: Global pharmaceutical company with a diverse product portfolio 🛡️ • Trend: Strong Q4 2024 earnings and reaffirmed 2025 guidance 🚀 Short commentary: Pfizer’s fundamentals are solid, with consistent revenue and earnings projections. 😉 (4/9) – KEY DEVELOPMENTS • Reaffirmed 2025 revenue guidance of $61-64 billion and EPS of $2.80-3.00 📈 • Continued focus on new drug developments and expanding into emerging markets 🌐 • Achieved cost savings goals and ongoing optimization programs for improved margins 💡 Short commentary: The company is managing its costs effectively and looking to future growth. Let’s watch closely. 👀 (5/9) – RISKS IN FOCUS • Legal challenges related to past products ⚙️ • Competition from generic manufacturers and patent expirations 📉 • Economic conditions affecting healthcare spending ⚠️ Short commentary: These risks are known, but Pfizer’s diverse portfolio should help mitigate them. Stay vigilant! 🕵️ (6/9) – SWOT: STRENGTHS • Diverse product portfolio across multiple therapeutic areas 🏆 • Strong R&D capabilities and pipeline of new drugs 🌈 • Global presence and distribution network 🌟 Short commentary: Pfizer’s strengths position it well for long-term growth. Keep up the good work! 👍 (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: Dependence on key products, legal issues ⚠️ • Opportunities: New drug approvals, expanding into emerging markets 🌐 Short commentary: Opportunities abound, but weaknesses need to be monitored. Let’s hope they nail it! 📈 (8/9) – PFE at $25.90 – what’s your call? 🗳️ • Bullish: Price could rise to $30+ if it breaks above $28 🚀 • Neutral: Price remains between $24 and $28 😐 • Bearish: Price could drop to $22 if it breaks below $24 📉 Drop your pick below! 💬 (9/9) – FINAL TAKEAWAY Pfizer’s $25.90 stance shows a company with solid fundamentals and a fair valuation at a P/E of approximately 8.93. With a strong pipeline and cost management, it’s an attractive option for value investors. Keep an eye on resistance at $28 for potential upside movement. Snag low, hold long!
NYSE:PFELong
by DCAChampion
PFE 1H Long Swing Conservative Trend TradeConservative Trend Trade + long impulse + SOS level + support level + 1/2 correction + biggest volumed Sp Calculated affordable stop limit 1 to 2 R/R take profit before 1/2 of the Month Expandable to 1/2 of the Year Daily Trend: "+ long impulse + neutral zone + close to 1/2 correction" Monthly CounterTrend "- short balance + unvolumed expanding ICE + volumed 2Sp- + weak test" Yearly Trend "+ long impulse + 1/2 correction + exhaustion volume?" Will add more if corrects to 1/2 of 1H wave.
NYSE:PFELong
by MishaSuvorov
PFE Operation PlanFor this trade on Pfizer (PFE), we will implement a staggered entry strategy with three designated entry points at $27, $26, and $25. This approach allows for a cost-averaging method and improved risk management as the market fluctuates. Our profit targets are set at $29, $30, and $31, ensuring we capture gains incrementally as the price moves upward. These targets are based on our technical analysis and current market dynamics. Additionally, strict stop-loss protocols will be in place to mitigate downside risks. Disclaimer: This information is provided for educational and informational purposes only and should not be considered financial advice. Trading involves substantial risk, and past performance is not indicative of future results. Always conduct your own research or consult a professional financial advisor before making any investment decisions.
NYSE:PFELong
by Robert_V12